ALX ONCOLOGY HOLDINGS INC (ALXO) Operating Margin
- Operating margin · 12 months: Value (m); Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | (m) | Operating income / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -82.55M USD | Operating Income (Loss) |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 61.83M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-82.55M | (m) | (m) | $61.83M | (m) | (m) |
| 2026-03-31 | $-91.17M | (m) | (m) | $66.71M | (m) | (m) |
| 2025-12-31 | $-104.02M | (m) | (m) | $77.00M | (m) | (m) |
| 2025-09-30 | $-111.61M | (m) | (m) | $82.88M | (m) | (m) |
| 2025-06-30 | $-121.65M | (m) | (m) | $91.91M | (m) | (m) |
| 2025-03-31 | $-136.53M | (m) | (m) | $108.54M | (m) | (m) |
| 2024-12-31 | $-142.47M | (m) | (m) | $116.37M | (m) | (m) |
| 2024-09-30 | $-159.88M | (m) | (m) | $134.63M | (m) | (m) |
| 2024-06-30 | $-180.59M | (m) | (m) | $153.92M | (m) | (m) |
| 2024-03-31 | $-175.84M | (m) | (m) | $148.75M | (m) | (m) |
| 2023-12-31 | $-170.28M | (m) | (m) | $141.79M | (m) | (m) |
| 2023-09-30 | $-154.47M | (m) | (m) | $125.21M | (m) | (m) |
| 2023-06-30 | $-137.88M | (m) | (m) | $108.82M | (m) | (m) |
| 2023-03-31 | $-134.89M | (m) | (m) | $106.09M | (m) | (m) |
| 2022-12-31 | $-127.44M | $0.00 | (m) | $98.40M | (m) | (m) |
| 2022-09-30 | $-123.69M | (m) | (m) | $94.10M | (m) | (m) |
| 2022-06-30 | $-111.58M | (m) | (m) | $82.93M | (m) | (m) |
| 2022-03-31 | $-94.09M | (m) | (m) | $67.39M | (m) | (m) |
| 2021-12-31 | $-83.56M | (m) | (m) | $60.17M | (m) | (m) |
| 2021-09-30 | $-72.91M | (m) | (m) | $51.42M | (m) | (m) |
| 2021-06-30 | $-58.14M | (m) | (m) | $38.53M | (m) | (m) |
| 2021-03-31 | $-52.63M | (m) | (m) | $34.98M | (m) | (m) |
| 2020-12-31 | $-43.66M | $1.18M | (m) | $28.96M | (m) | -3693.99% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-19.18M | $4.80M | (m) | $16.31M | (m) | -399.98% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $-13.68M | $2.07M | (m) | $11.27M | (m) | -662.02% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |